Timothy J Kruser

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5270362/publications.pdf

Version: 2024-02-01

112 3,187 25 54
papers citations h-index g-index

112 112 112 4497
all docs docs citations times ranked citing authors

#	Article	IF	Citations
1	Recommended first-line management of brain metastases from melanoma: A multicenter survey of clinical practice. Radiotherapy and Oncology, 2022, 168, 89-94.	0.6	4
2	Fast and Furious: New Data Examining Accelerated Radiation Therapy for Limited-Stage Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2022, 112, 1067-1070.	0.8	0
3	Tumor-associated alterations in white matter connectivity have prognostic significance in MGMT-unmethylated glioblastoma. Journal of Neuro-Oncology, 2022, 158, 331-339.	2.9	1
4	Mean Brain Dose Remains Uninfluenced by the Lesion Number for Gamma Knife Stereotactic Radiosurgery for 10+ Metastases. World Neurosurgery, 2022, 165, e380-e385.	1.3	2
5	Long-term outcomes of spinal ependymomas: an institutional experience of more than 60 cases. Journal of Neuro-Oncology, 2021, 151, 241-247.	2.9	9
6	The Evolution and Future of the American Society for Radiation Oncology (ASTRO) Clinical Practice Guidelines: A Report From the ASTRO Methodology Work Group on Behalf of the Guideline Subcommittee. Practical Radiation Oncology, 2021, 11, 30-34.	2.1	1
7	58P Outcome and toxicity of reirradiation for locally recurrent small cell lung cancer: An international multicenter study. Journal of Thoracic Oncology, 2021, 16, S727.	1.1	O
8	Radiotherapy for Metastatic Non–Small Cell Lung Cancer. Advances in Oncology, 2021, 1, 15-28.	0.2	1
9	Strike or Spare? A Review of Lung-Sparing Therapies for Malignant Pleural Mesothelioma. International Journal of Radiation Oncology Biology Physics, 2021, 110, 257-260.	0.8	O
10	Current Landscape and Future Prospects of Radiation Sensitizers for Malignant Brain Tumors: A Systematic Review. World Neurosurgery, 2021, 151, e839-e856.	1.3	3
11	Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation. Translational Lung Cancer Research, 2021, 10, 3608-3615.	2.8	5
12	A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas. Journal of Neuro-Oncology, 2021, 155, 297-306.	2.9	5
13	Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas. Neuro-Oncology, 2020, 22, 470-479.	1.2	49
14	A multi-institutional analysis of clinical outcomes and patterns of care of 1p/19q codeleted oligodendrogliomas treated with adjuvant or salvage radiation therapy. Journal of Neuro-Oncology, 2020, 146, 121-130.	2.9	4
15	Cost-effectiveness of lung MRI in lung cancer screening. European Radiology, 2020, 30, 1738-1746.	4.5	23
16	Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. Journal of Clinical Oncology, 2020, 38, 3773-3784.	1.6	223
17	Medical oncologist perspectives on palliative care reveal physician-centered barriers to early integration. Annals of Palliative Medicine, 2020, 9, 2800-2808.	1.2	11
18	Prognostic factors and outcome of reirradiation for locally recurrent small cell lung cancerâ€"a multicenter study. Translational Lung Cancer Research, 2020, 9, 232-238.	2.8	7

#	Article	IF	CITATIONS
19	Survival of Primary Stereotactic Body Radiation Therapy Compared With Surgery for Operable Stage I/II Non-small Cell Lung Cancer. Annals of Thoracic Surgery, 2020, 110, 228-234.	1.3	29
20	Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro-Oncology, 2020, 22, 1359-1367.	1.2	49
21	Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today. International Journal of Radiation Oncology Biology Physics, 2020, 107, 334-343.	0.8	81
22	Hippocampal Avoidance During Whole-Brain Radiotherapy Plus Memantine for Patients With Brain Metastases: Phase III Trial NRG Oncology CC001. Journal of Clinical Oncology, 2020, 38, 1019-1029.	1.6	483
23	Radiation Therapy for Small Cell Lung Cancer: An ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2020, 10, 158-173.	2.1	111
24	Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a STK11 mutation Journal of Clinical Oncology, 2020, 38, 9033-9033.	1.6	2
25	Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer. Journal of Thoracic Disease, 2020, 12, 6690-6700.	1.4	25
26	A Time to Ignore "No Meat, No Treat― International Journal of Radiation Oncology Biology Physics, 2019, 105, 245-246.	0.8	0
27	RADI-08. A SURVEY BASED STUDY OF BRAIN METASTASES MANAGEMENT FOR PATIENTS WITH NON-SMALL CELL LUNG CANCERS OR MELANOMA. Neuro-Oncology Advances, 2019, 1, i23-i23.	0.7	0
28	What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?. Translational Lung Cancer Research, 2019, 8, S153-S162.	2.8	27
29	Radiation Oncologists' Role in End-of-Life Care: A Perspective From Medical Oncologists. Practical Radiation Oncology, 2019, 9, 362-370.	2.1	11
30	Pleomorphic xanthoastrocytoma: a brief review. CNS Oncology, 2019, 8, CNS39.	3.0	53
31	Stereotactic radiosurgery and fractionated radiotherapy for spinal arteriovenous malformations – A systematic review of the literature. Journal of Clinical Neuroscience, 2019, 62, 83-87.	1.5	10
32	Lymphopenia predicts response to stereotactic radiosurgery in lung cancer patients with brain metastases. Journal of Neuro-Oncology, 2019, 143, 337-347.	2.9	15
33	Systemic and local immunosuppression in patients with high-grade meningiomas. Cancer Immunology, Immunotherapy, 2019, 68, 999-1009.	4.2	28
34	NRG brain tumor specialists consensus guidelines for glioblastoma contouring. Journal of Neuro-Oncology, 2019, 143, 157-166.	2.9	58
35	Symptomatic radiation necrosis in brain metastasis patients treated with stereotactic radiosurgery and immunotherapy. Clinical Neurology and Neurosurgery, 2019, 179, 14-18.	1.4	32
36	CMET-11. RESPONSE TO STEREOTACTIC RADIOSURGERY FOR MULTIPLE BRAIN METASTASES BASED ON HISTOLOGY-SPECIFIC SUBTYPE STATUS. Neuro-Oncology, 2019, 21, vi53-vi53.	1.2	0

#	Article	IF	Citations
37	OA03.03 Multi-Institutional Study of Pneumonitis After Treatment with Durvalumab and Chemoradiotherapy for Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S1131-S1132.	1.1	2
38	Stereotactic radiosurgery for the treatment of brain metastasis from gastrointestinal primary cancers. Journal of Radiosurgery and SBRT, 2019, 6, 27-34.	0.2	0
39	Objective Evaluation of a Didactic Curriculum for the Radiation Oncology Medical Student Clerkship. International Journal of Radiation Oncology Biology Physics, 2018, 101, 1039-1045.	0.8	31
40	One size does not fit all: Nuances in postoperative N2Ânon–small cell lung cancer management. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 370-373.	0.8	2
41	Postsurgical Cavity Evolution After Brain Metastasis Resection: How Soon Should Postoperative Radiosurgery Follow?. World Neurosurgery, 2018, 110, e310-e314.	1.3	22
42	Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma. Cancer, 2018, 124, 734-742.	4.1	68
43	Radiation Oncology Education for Medical Oncology Fellowship Trainees: A Pilot Needs Assessment. International Journal of Radiation Oncology Biology Physics, 2018, 102, e395.	0.8	1
44	Oligodendroglioma Patients with $1p/19q$ Co-deletion Treated with Early or Delayed Radiation Therapy over the Last Two Decades: A Multi-institutional Report. International Journal of Radiation Oncology Biology Physics, 2018, 102, e282-e283.	0.8	1
45	Outcomes in BRAFV600e-Mutant Melanoma Brain Metastases Managed with Radiosurgery: A Multi-Institutional Assessment of Craniotomy Mitigation. International Journal of Radiation Oncology Biology Physics, 2018, 102, e212.	0.8	1
46	Stereotactic Body Radiation Therapy to Multiple Sites of Intrathoracic Disease: A Multi-Institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2018, 102, e683.	0.8	0
47	ATIM-02. TUMOR TREATING FIELDS IN COMBINATION WITH BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA IN A PHASE 2 STUDY. Neuro-Oncology, 2018, 20, vi1-vi1.	1.2	1
48	Consensus Radiation Therapy Contouring Guidelines for Glioblastoma, Based on NRG Recommendations. International Journal of Radiation Oncology Biology Physics, 2018, 102, e351.	0.8	0
49	RTHP-32. RECONSIDERING THE PROGNOSTIC IMPACT OF AGE, GRADE, AND EXTENT OF RESECTION ON CLINICAL OUTCOMES OF $1p/19q$ CODELETED OLIGODENDROGLIOMAS AFTER RADIATION THERAPY: A MULTI-INSTITUTIONAL REPORT. Neuro-Oncology, 2018, 20, vi231-vi232.	1.2	0
50	QOLP-25. QUALITY OF LIFE FOLLOWING RE-IRRADIATION FOR RECURRENT HIGH GRADE GLIOMA. Neuro-Oncology, 2018, 20, vi220-vi220.	1.2	2
51	NCOG-01. PRESERVATION OF NEUROCOGNITIVE FUNCTION (NCF) WITH HIPPOCAMPAL AVOIDANCE DURING WHOLE-BRAIN RADIOTHERAPY (WBRT) FOR BRAIN METASTASES: PRELIMINARY RESULTS OF PHASE III TRIAL NRG ONCOLOGY CC001. Neuro-Oncology, 2018, 20, vi172-vi172.	1.2	14
52	EP-1651: Radiation oncologists' role in end-of-life care: a view from medical oncologists. Radiotherapy and Oncology, 2018, 127, S888-S889.	0.6	0
53	Intracranial Response to Anti-Programmed Death 1 Therapy in a Patient with Metastatic Non-Small Cell Lung Cancer with Leptomeningeal Carcinomatosis. Oncologist, 2018, 23, e159-e161.	3.7	6
54	Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation. Lancet Oncology, The, 2018, 19, e366.	10.7	10

#	Article	IF	CITATIONS
55	An overview of meningiomas. Future Oncology, 2018, 14, 2161-2177.	2.4	300
56	Postoperative stereotactic radiosurgery for patients with resected brain metastases: a volumetric analysis. Journal of Neuro-Oncology, 2018, 140, 395-401.	2.9	6
57	Barriers to early integration of palliative care: A qualitative analysis of medical oncologist attitudes and practice patterns Journal of Clinical Oncology, 2018, 36, e22191-e22191.	1.6	1
58	Abstract CT081: Tumor treating fields in combination with Bevacizumab in recurrent or progressive meningioma in a phase II study. , $2018, , .$		0
59	Radiotherapy for cranial and brain metastases from prostate cancer: a systematic review. Journal of Neuro-Oncology, 2017, 133, 531-538.	2.9	16
60	Cavity Dynamics Prior to Stereotactic Radiosurgery for Resected Brain Metastases: Are They Growing?. International Journal of Radiation Oncology Biology Physics, 2017, 99, E91.	0.8	0
61	Glioblastoma Multiforme in Diabetic Patients: Impact of Hyperglycemia, Comorbidities, and Medications on Outcomes. International Journal of Radiation Oncology Biology Physics, 2017, 99, E100.	0.8	0
62	Primary medical therapy for BRAFV600E-mutant melanoma brain metastasesâ€"is this good enough?. Lancet Oncology, The, 2017, 18, e508.	10.7	0
63	Clinical Outcomes Following Stereotactic Body Radiation Therapy to Multiple Sites of Intrathoracic Disease. International Journal of Radiation Oncology Biology Physics, 2017, 98, 250-251.	0.8	0
64	(P090) Stereotactic Radiosurgery for Brain Metastases From Primary Head and Neck Carcinomas: A Retrospective Analysis. International Journal of Radiation Oncology Biology Physics, 2017, 98, E39-E40.	0.8	0
65	Intensive Care Unit Outcomes Among Patients With Cancer After Palliative Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2017, 99, 854-858.	0.8	5
66	Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis. Journal of Neuro-Oncology, 2017, 134, 197-203.	2.9	7
67	Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation. Journal of Neuro-Oncology, 2017, 134, 331-338.	2.9	21
68	ACTR-19. AÂPHASE 2 STUDY OF TUMOR TREATING FIELDS AND BEVACIZUMAB IN RECURRENT OR PROGRESSIVE MENINGIOMA. Neuro-Oncology, 2017, 19, vi4-vi4.	1.2	0
69	ACTR-88. AÂPHASE II STUDY OF THE EFFICACY OF HYPOFRACTIONATED RADIATION THERAPY WITH BEVACIZUMAB AND TEMOZOLOMIDE FOLLOWED BY MAINTENANCE TEMOZOLOMIDE AND BEVACIZUMAB FOR RECURRENT HIGH-GRADE GLIOMAS. Neuro-Oncology, 2017, 19, vi19-vi20.	1.2	O
70	Getting to the Heart of the Matter: What Additional Proof Is Needed to Demonstrate the Value of Intensity-Modulated Radiotherapy in Thoracic Oncology?. Journal of Clinical Oncology, 2017, 35, 2215-2216.	1.6	1
71	Single Fraction Stereotactic Radiosurgery for Retreatment of Skull Base Recurrent Head and Neck Malignancies. Cureus, 2017, 9, e1206.	0.5	4
72	ATIM-10. PHASE I/II TRIAL OF RADIATION THERAPY, TEMOZOLOMIDE AND PEMBROLIZUMAB FOLLOWED BY TEMOZOLOMIDE AND PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. Neuro-Oncology, 2016, 18, vi19-vi19.	1.2	1

#	Article	IF	CITATIONS
73	Advancements in unresectable melanoma: a multidisciplinary perspective. Melanoma Management, 2016, 3, 171-175.	0.5	O
74	Systemic Therapy in Unresectable Meningioma Before Radiotherapy. Journal of Clinical Oncology, 2016, 34, 1826-1827.	1.6	2
75	Chemoradiation for organ preservation in the treatment of muscle-invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 271-278.	1.6	8
76	Updated Analysis of a Multi-Institutional Radiation Oncology Clerkship Curriculum: A Report From the Radiation Oncology Education Collaborative Study Group. International Journal of Radiation Oncology Biology Physics, 2016, 96, E412.	0.8	0
77	Outcomes After Intensive Care Unit Admission for Patients Receiving Palliative Radiation Therapy: A Missed Opportunity for Goals of Care Discussions. International Journal of Radiation Oncology Biology Physics, 2016, 96, E508.	0.8	0
78	Identification of Patients Who Benefit From Bevacizumab in High-Grade Glioma—An Easy Question Turned Difficult: Treat the Scan or the Patient?. Journal of Clinical Oncology, 2016, 34, 1281-1282.	1.6	6
79	Long-term Efficacy and Toxicity of Hypofractionated Salvage Radiation Therapy for Biochemically Recurrent Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2015, 93, E186.	0.8	0
80	Phase 1 Trial of Bevacizumab With Concurrent Chemoradiation Therapy for Squamous Cell Carcinoma of the Head and Neck With Exploratory Functional Imaging of Tumor Hypoxia, Proliferation, and Perfusion. International Journal of Radiation Oncology Biology Physics, 2015, 91, 942-951.	0.8	44
81	Choroid plexus tumor epidemiology and outcomes: implications for surgical and radiotherapeutic management. Journal of Neuro-Oncology, 2015, 121, 151-157.	2.9	53
82	Reirradiation for Locoregionally Recurrent Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 70-76.	1.3	37
83	Uncertainty in Rectal Tumor Localization During Preoperative Radiation and the Impact of Distal Tumor Delineation on Normal Tissue Dosimetry. International Journal of Radiation Oncology Biology Physics, 2013, 87, S331-S332.	0.8	0
84	Risk of Cerebrovascular Events in Elderly Patients After Radiation Therapy Versus Surgery for Early-Stage Glottic Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 290-296.	0.8	32
85	Pseudoprogression after glioma therapy: a comprehensive review. Expert Review of Neurotherapeutics, 2013, 13, 389-403.	2.8	92
86	Acute Hematologic and Mucosal Toxicities in Head and Neck Cancer Patients Undergoing Chemoradiotherapy: A Comparison of 3D-CRT, IMRT, and Helical Tomotherapy. Technology in Cancer Research and Treatment, 2013, 12, 383-389.	1.9	12
87	Combined Chemoradiation Therapy in the Treatment of Squamous Cell Carcinoma of the Head and Neck—An Evolving Paradigm. Oncology & Hematology Review, 2013, 09, 115.	0.2	O
88	Sublobar Resection With Intraoperative 125I Brachytherapy Versus Stereotactic Body Radiation Therapy for Treatment of Clinical Early-Stage Non-small Cell Lung Cancer in Patients not Eligible for Lobectomy. International Journal of Radiation Oncology Biology Physics, 2012, 84, S46-S47.	0.8	0
89	Impact of Radiation Therapy and Extent of Resection in Choroid Plexus Carcinoma: An Analysis of the Surveillance, Epidemiology, and End Results (SEER) Database. International Journal of Radiation Oncology Biology Physics, 2012, 84, S303.	0.8	1
90	Low Rates of Heterotopic Ossification After Resurfacing Hip Arthroplasty With Use of Prophylactic Radiotherapy in Select Patients. Journal of Arthroplasty, 2012, 27, 1349-1353.	3.1	5

#	Article	IF	Citations
91	Principles and Application of PET in Brain Tumors. PET Clinics, 2011, 6, 131-148.	3.0	1
92	Papillary Serous and Clear Cell Adenocarcinoma of the Uterus: A 10-Year Single-Institution Experience. International Journal of Radiation Oncology Biology Physics, 2011, 81, S471-S472.	0.8	0
93	Early hypofractionated salvage radiotherapy for postprostatectomy biochemical recurrence. Cancer, 2011, 117, 2629-2636.	4.1	67
94	The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients. Expert Opinion on Investigational Drugs, 2011, 20, 305-307.	4.1	7
95	Prognostic factors for complete obliteration of arteriovenous malformations treated with LINAC-based stereotactic radiosurgery. Journal of Radiosurgery and SBRT, 2011, 1, 203-211.	0.2	0
96	Mechanisms of resistance to HER family targeting antibodies. Experimental Cell Research, 2010, 316, 1083-1100.	2.6	136
97	Tomo Challenge: Results of Multi-institution Planning Exercise and Development of an Objective Plan Assessment Tool. International Journal of Radiation Oncology Biology Physics, 2010, 78, S749-S750.	0.8	0
98	Augmentation of Radiation Response by Motesanib, a Multikinase VEGF Receptor Inhibitor. International Journal of Radiation Oncology Biology Physics, 2010, 78, S115.	0.8	0
99	Patterns of First Recurrence after Adjuvant Radiotherapy in Papillary Serous and Clear Cell Carcinoma of the Uterus. International Journal of Radiation Oncology Biology Physics, 2010, 78, S420.	0.8	O
100	Augmentation of Radiation Response by Motesanib, a Multikinase Inhibitor that Targets Vascular Endothelial Growth Factor Receptors. Clinical Cancer Research, 2010, 16, 3639-3647.	7.0	14
101	The Impact of Hybrid PET-CT Scan on Overall Oncologic Management, with a Focus on Radiotherapy Planning: A Prospective, Blinded Study. Technology in Cancer Research and Treatment, 2009, 8, 149-158.	1.9	31
102	Epidermal Growth Factor Receptor cooperates with Src Family Kinases in acquired resistance to cetuximab. Cancer Biology and Therapy, 2009, 8, 696-703.	3.4	138
103	Computed Tomography Finding Mimicking Aortic Dissection after Cabrol Procedure. Asian Cardiovascular and Thoracic Annals, 2009, 17, 108-109.	0.5	7
104	Multidisciplinary management of colorectal brain metastases. Cancer, 2008, 113, 158-165.	4.1	64
105	Augmentation of Radiation Response by Panitumumab in Models of Upper Aerodigestive Tract Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 534-542.	0.8	41
106	Prognostic Factors for Complete Obliteration of Arteriovenous Malformations Treated with LINAC-Based Stereotactic Radiosurgery. International Journal of Radiation Oncology Biology Physics, 2008, 72, S202.	0.8	1
107	Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene, 2008, 27, 3944-3956.	5.9	497
108	Recurrent Syncope Secondary to Asystole in an Infant With Wolff-Parkinson-White Syndrome. Clinical Pediatrics, 2008, 47, 701-704.	0.8	2

#	Article	IF	CITATIONS
109	Acquired Resistance to Cetuximab: Rationale for Sequential Therapies Directed Against the EGFR. International Journal of Radiation Oncology Biology Physics, 2007, 69, S138.	0.8	O
110	A Prospective Study Comparing CT-Based to PET/CT-based Radiation Treatment Planning. International Journal of Radiation Oncology Biology Physics, 2007, 69, S68-S69.	0.8	1
111	Multidisciplinary Management of Colorectal Cancer Brain Metastases: A Retrospective Study. International Journal of Radiation Oncology Biology Physics, 2007, 69, S250.	0.8	O
112	Panitumumab, a Fully Human Anti-EGFR Monoclonal Antibody, Augments Radiation Response in Xenograft Models of Upper Aerodigestive Tract Cancers. International Journal of Radiation Oncology Biology Physics, 2007, 69, S615-S616.	0.8	3